ABSTRACT
INTRODUCTION
Type 2 diabetes mellitus (Type 2 DM) is a common metabolic disease, characterized by glycaemia > 1.26 g/L (7 mmol/L), that could be associated with many co-morbidities including nephropathy (1−2). Type 2 diabetes mellitus affects many ethnic groups in Tunisia (3) and diabetic nephropathy is considered the most frequent cause of end-stage renal disease (ESRD) in Africa and developing countries (4) . Clinical analysis has implicated several different factors in nephropathy (5−6) with a possible genetic predisposition (7) . Strong risk factors include sustained hyperglycaemia, hypertension, smoking and obesity. Whereas weak risk factors are dyslipidaemia and physical inactivity. A large body of work characterized nephropathy, a microvascular disease, with a progressive albuminuria, and a decrease of the glomerular filtration rate [GFR] (6, 8) . The increased body mass index (BMI) associated with hypertension makes the Type 2 DM population in Tunisia more susceptible to nephropathy. This study focusses on diabetic nephropathy in order to improve Type 2 DM patients' outcome and to avoid significant associated morbidity and mortality. Early detection of nephropathy may prevent end stage kidney disease.
SUBJECTS AND METHODS
This study used data generated from 115 Tunisian adults who visited the Basic Health Group of Sousse over two years (2008) (2009) (2010) . Patients, who gave their consent, were included if they had Type 2 DM (73 patients, sex ratio male/ females 0.3) or not (42 healthy volunteers as normal controls, sex ratio male/females 0.3). Type 2 diabetes mellitus was diagnosed after at least two separate overnight fasting venous plasma glucose concentrations above 6.1 mmol/L (9), or above 126 mg/dL by the American Diabetes Association (ADA) criteria (10) . Patients were excluded from the study if they had Type 1 DM, or active chronic inflammatory diseases or had been treated with chemotherapy for cancer.
We recorded the main clinical markers in all subjects, co-morbidities (macrovascular and microvascular complications including retinopathy, polyneuritis, nephropathy), family history of diabetes, year of diabetes diagnosis, tobacco consumption, and other pharmacological treatments. Type 2 DM was treated by insulin and/or oral hypoglycaemic agents (10) .
Diabetic nephropathy was diagnosed in the presence of microalbuminuria or proteinuria. Diabetic retinopathy was diagnosed by ophthalmological fundoscopic examination recognizing the features of the eye changes in diabetes. Hypertension was considered if the blood pressure was more than 140/90 mmHg according to ADA criteria (11), or if the patient was taking anti-hypertensives.
Blood pressure, weight and height measurements were performed. Systolic and diastolic blood pressures were taken with a standard manual sphygmomanometer. Normal blood pressure was taken as < 130/80 mmHg. The BMI (kg/m 2 ) was also determined. A BMI of ≥ 30 kg/m 2 was an indicator of obesity.
Standard biological parameters including the haemogram were measured under fasting conditions on the same day of the clinical examination. Venous plasma glucose was measured by the glucose oxidase method with an automated spectrophotometer A25-autoanalyzer (Biosystems). Glycated haemoglobin molecule (HbA 1c ) measurement (normal range 4−5.5%) was carried out by turbidimetric inhibition immunoassay with the Cobas c 111 analyser (Roche). Serum lipid levels (total cholesterol, triglycerides, high-and low density lipoprotein (HDL, LDL)) were performed by enzymatic methods using the Vitalab Flexor E (Vital Scientific).
Liver enzyme levels including aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured for all patients. The following parameters were measured to define renal function: urea, creatinine, microalbuminuria, and creatinine clearance (CC). Microalbuminuria was defined as < 2.8 g/mol for women and < Table 2 indicates that sulfonylurea was taken alone in 11.9% of Type 2 DM patients, and in combination with other drugs in 40.3% of patients.
Several gender differences were noticed ( Table 1 ). The BMI for women was 31.6 (0.7) kg/m 2 and 26.3 (1.2) kg/m 2 for men. Obesity is estimated at 60% for women and 23% for men explaining the enhanced lipid-lowering agents used by women. Women had significantly higher CC, whereas g/mol for men (12) . Estimated GFR (normal range > 60 mL/min/1.73 m 2 ), an important marker of renal function, was calculated according to the Modified Diet in Renal Disease (MDRD) formula based on serum creatinine concentration, age, race, and gender (13−16) . Glomerular filtration rate stages were classified as previously described (6) .
Statistical analysis was performed using the statistical software GraphPad Prism (version 5.01). Descriptive data were analysed using means, standard error of the mean (SE), percentages and variances. Data are expressed as means (SE). Comparison of quantitative variables was performed using the two-tailed Student's t-test, whereas comparison of qualitative variables was performed by Chi-square test. Linear regression and Pearson correlation were used to evaluate the associations and the correlation between kidney factors. Statistical significance was inferred at p < 0.05. men had significantly higher creatinine, urea levels, and haemoglobin percentage (Table 1 ). In addition, men had more significant smoking habits than women. Patients with Type 2 DM were affected by various comorbidities. Macrovascular disease and retinopathy were significantly enhanced in males compared to women. Women were more likely to have polyneuritis, even though not significant, compared with men. Family history of diabetes was significantly more for women.
Factors associated with nephropathy
Normal CC range is between 80−140 mL/min. Healthy Tunisian patients (controls) had creatinine clearance 104.5 (4.7) mL/min (Table 3 ). All Type 2 DM patients had lower CC (78.7 (2.8) mL/min). In the same manner, when the Type 2 DM group with nephropathy was excluded, CC level of Type 2 DM patients without nephropathy was 78.6 (3) mL/min. Difference between CC in Type 2 DM with/without nephropathy, and healthy volunteers was significant (p < 0.0001, Table 3 ). The comparison of other renal parameters including urea, creatinine and microalbuminuria for Type 2 DM with/without nephropathy and healthy volunteers were not statistically significant (Table 3) . Table 4 reveals that the mean age of Type 2 DM patients with nephropathy was 62.7 (4) years. The clinical characteristics of this group and Type 2 DM without nephropathy group are given in Table 4 . The serum levels of creatinine and urea in the Type 2 DM with nephropathy group were statistically significantly higher than the Type 2 DM without nephropathy group. Family history of diabetes was also higher in the Type 2 DM with nephropathy group than in the Type 2 DM without nephropathy group. Seventyfive per cent of Type 2 DM patients with nephropathy were taking antihypertensives without significant increase of macrovascular disease. Twenty-five per cent of Type 2 DM patients with nephropathy were taking lipid-lowering agents.
This percentage was significantly different from the percentage of Type 2 DM patients without nephropathy. Type 2 diabetes mellitus patients with nephropathy had detectable retino-pathy but the difference was on the border of statistical significance. No significant differences in polyneuritis were noted between the two groups (Table 4) .
Although 63% of diabetics taking sulfonylurea were Type 2 DM with nephropathy, 54% and 8% of Type 2 DM diabetics taking biguanides and glitazones, respectively, were Type 2 DM patients without nephropathy. Differences between groups for each hypoglycaemic therapy were statistically significant (Table 4) . The other oral agents as well as insulin therapy were not different between Type 2 DM patients with/without nephropathy ( Table 4 ). In addition, use of angiotensin converting enzyme (ACE) inhibitor therapy was not different between the two diabetic groups.
When we focus on women with diabetic nephropathy, we found that urea and creatinine levels were significantly increased compared with women without nephropathy ( Table  5) . Seventeen per cent of these women with diabetic nephropathy smoked and probably had underlying genetic risk factors. The majority of the women were taking antihypertension agents (83%), as well as lipid-lowering agents (33%). Differences between diabetic women with/without nephropathy in terms of drugs taken were statistically significant (Table 5 ). Diabetic women with nephropathy had detectable macrovascular disease and polyneuritis but the difference was on the border of statistical significance.
Creatinine and urea were found to be significantly correlated in Pearson analysis for all diabetics (Table 6A) as well as for women (Table 6B ). These kidney markers were also associated in the two groups. Microalbuminuria and urinary CC were not correlated in all Type 2 DM patients and in women (Table 6 ). However, these latter parameters were associated only for the diabetic women cohort (Table 6B) .
Urinary CC and diabetes duration in Type 2 DM patients with/without nephropathy are shown in Fig. 1 . Diabetic pa-tients with nephropathy showed a comparable mean (SE) of CC [79.1 (8.7) mL/min] and diabetics without Table 4 ). The intra-groups variance is illustrated in Fig. 1A . This deficient urinary CC in diabetics is independent from disease duration (Fig. 1B) . Figure 2 shows the GFR estimated according to the MDRD formula in diabetic patients without nephropathy. Mean GFR within this group was 76 mL/min/1.73m 2 . Table  7 indicates the GFR percentages in all Type 2 DM patients without nephropathy, by gender. Of Type 2 DM patients without nephropathy, 1.5% presented with a GFR < 60 mL/min/1.73 m 2 (Stage 3: mild to moderate) indicating a probable kidney malfunction. Seventy-six per cent had GFR between 60 and 89 mL/min/1.73 m 2 (Stage 2: mild). In contrast, only 22.5% had a GFR over 90 mL/min/1.73 m 2 [Stage 1: increased and optimal] ( Table 7) . Gender differences were also noticed.
Differences between GFR of Type 2 DM patients with/without nephropathy were not significant (Fig. 3) except for men. Intra-group GFR variance was significant for the entire cohort and for women (Fig. 3) . However, intra-group GFR variance was not significant in the male group (Fig 3) . Regarding diabetic complications associated with nephropathy, the prevalence of retinopathy in Type 2 DM patients without nephropathy is close to that of Type 2 DM patients with nephropathy for the entire cohort, women but not for men. In addition, the inter-group variance within diabetics without nephropathy and retinopathy was reduced (Fig. 3 ). Type 2 diabetes mellitus patients without nephropathy including those with/without retinopathy have similar GFR as patients with nephropathy [no statistical differences for the entire cohort and for women] (Fig. 3) . However, this is not the case for men. Bouaziz et al (21) . However, in this stage, kidney function starts to decrease (22) . This result should be confirmed by urinalysis, imaging or biopsies (6) . However, the GFR calculation alone could be sufficient for Type 2 DM patients with nephropathy (1.5%; GFR stage 3). For this stage, GFR may be supranormal but declining (21) . This means that preventive treatment should be started. These patients should be monitored regularly for their GFR and should contact a nephrologist to slow progression of kidney disease. Moreover, GFR measures should be performed especially because normal albuminuria may denote incipient GFR reduction in Type 2 DM patients (23) . Support should be provided for patients at GFR stages 2 and 3 especially if they are overweight or obese. This support becomes important for the Tunisian obese population that frequently demonstrated the metabolic syndrome (24) . The National Kidney Foundation (NKF) recommends decreasing BMI to 18.5−24.9 kg/m 2 for patients with diabetes (25) . Moreover, a protein restriction to 0.8 g/kg seems reasonable for these patients (21) . In addition, diabetic drugs should be correctly selected (6, 26) . For example, sulfonylureas should not be associated with other medications to lessen the plasma levels of free sulfonylureas (27−28) . Type 2 diabetes mellitus Tunisian patients with nephropathy should be monitored closely. Indeed, HbA 1c should decrease from the noted value (8.5%) and be maintained < 7% (2, 6) . Continuous monitoring of blood pressure (29−30) , serum lipids and albumin rates should be checked to avoid more complications of Type 2 DM (7, 31) .
Smoking cessation may be beneficial for Type 2 DM Tunisian patients, particularly men (32−33) . In addition, patients should be on a special low-protein diet to slow progression to end-stage renal failure and dietary restrictions to decrease their obesity (34) (35) (36) . Moreover, physicians may subscribe more lipid-lowering agents like statins to reduce the LDL levels to < 2.59 mmol/L (37) .
The susceptibility of Tunisians from the region of Sousse to diabetic nephropathy, indicated by GFR of stage 2 and 3, necessitates treatment with ACE inhibitors (38) or angiotensin receptor blockers to prevent or to delay progression (1, (39) (40) (41) . These drugs could be efficient especially because the renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility of Tunisian Type 2 DM populations to nephropathy (42) . The administration of other drugs including diuretics, betablockers, and calcium-channel blockers may also be beneficial for certain patients with diabetic nephropathy (1).
The screening for diabetic retinopathy should also be performed annually in Type 2 DM Tunisian patients from Sousse especially after the clinical studies demonstrating that retinopathy could indicate a potential development of nephropathy (43−45) . Indeed, Type 2 DM patients with retinopathy and proteinuria frequently have nephropathy (45) . Emerging studies exploring these complications in Type 2 DM support the association of retinopathy and nephropathy (45) . However, the absence of retinopathy does not exclude nephropathy (45−46) .
CONCLUSION
This study demonstrates the susceptibility of Tunisian Type 2 DM patients from Sousse to nephropathy. The regular monitoring of these patients should delay the onset of this co-morbidity. Moreover, the achievement of the ADA targets should be very helpful as demonstrated in other populations (7, 47) . Finally, frequent GFR measurements should be performed.
